×
Home
Archive Submission Guidelines
News Contact
Review article
Crossmark

A comprehensive review of COVID-19 treatment

By
Zeinab Afshar ,
Zeinab Afshar
Arefeh Babazadeh ,
Arefeh Babazadeh
Mostafa Javanian ,
Mostafa Javanian
Mohammad Barary ,
Mohammad Barary
Vasigala Rekha ,
Vasigala Rekha
Soheil Ebrahimpour
Soheil Ebrahimpour

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus strain that caused coronavirus disease 2019 (COVID-19). This novel coronavirus is an emerging global health threat. It caused approximately 140 million confirmed cases, with about 3 million deaths worldwide until April 18, 2021. Although there are two approved medications for this disease, remdesivir and dexamethasone, numerous studies are underway to investigate more therapeutic options. However, so far, most treatments have been supportive, and the clinical efficacy of the suggested drugs is still under consideration. The purpose of this review is to summarize the ongoing treatments, such as several antivirals, convalescent plasma transfusion, and adjunctive medications, with the intent of serving as a clinical guide for the physician and a resource for further evaluations in various clinical trials.

References

1.
Wise J. Covid-19: Arthritis drugs improve survival in intensive care patients, shows study. BMJ. :n61.
2.
Marin GH. Facts and reflections on COVID-19 and anti-hypertensives drugs. Drug Discoveries & Therapeutics. 2020;14(2):105–6.
3.
Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(3):211–2.
4.
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine. 2020;382(17):1653–9.
5.
Li Y, Shi K, Qi F, Yu Z, Chen C, Pan J, et al. Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study. International Journal of Infectious Diseases. 2021;103:507–13.

Citation

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.